secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-RAD LABORATORIES, INC. (BIO)
CIK:        0000012208
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0000012208-24-000036
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Rad Q1 net sales down 9.8% to $610.8M; Life Science segment falls 25.3% YoY
-------------------------------------------------------------------------------

- Net sales $610.8M, down 9.8% YoY (currency-neutral -9.6%); operating income $44.7M vs $61.9M.
- Life Science segment $241.7M (-25.3% YoY) due to biotech/biopharma weakness; Clinical Diagnostics $368.6M (+4.7%) grew.
- Net income $383.9M ($13.45 diluted) vs $69.0M ($2.32), largely from fair value changes of Sartorius AG equity holdings.
- CEO Norman Schwartz: Q1 in line with expectations; cautiously optimistic for gradual biopharma recovery in H2 2024.
- Effective tax rate 21.8% vs 18.7% a year ago, affected by equity securities treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/12208/000001220824000036/0000012208-24-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/12208/000001220824000036/bio-20240507.htm
  HTML page:      https://secwatch.observer/filing/0000012208-24-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer